Your retirement savings are at risk in a clearly insane stock market

• The stock market is trying to break out — but the bulls can’t catch a break

  S&P 500 is stuck in a trading range.
  
  MarketWatch - 16h

• Tech stocks seem to have ended their ‘difficult relationship’ with the bond market

  At least for now, U.S. large-cap technology and growth stocks appear “free of their difficult relationship with long-term yields,” according to DataTrek Research.
  
  MarketWatch - 15h

• Singapore regulator to inject $4bn into stock market to boost listings

  Authorities also announce tax incentives as part of package designed to revive struggling equity market
  
  Financial Times - 6h

• The stock market is expensive. But there’s still one bull case not priced in, says Bank of America.

  Bank of America says heavily regulated sectors have yet to fully rally
  
  MarketWatch - 4h

• This stock sector can still soar during the late stages of the bull market — and there are easy ways to play it

  Also: Nvidia earnings on deck, potential stock splits and big gains, a look at gold, and the Moneyist pulls no punches.
  
  MarketWatch - 2h

• President Trump is losing the stock market war to the rest of the world so far. Here's where investors are taking advantage

  Emerging market stocks, China and European stocks are beating U.S. indexes since the inauguration of Donald Trump.
  
  CNBC - 3h

• McConnell announces retirement from the Senate

  Politico - 1d

• Trump says he's weighing giving 20% of DOGE savings to Americans

  President Donald Trump revealed Wednesday that he's considering sending 20% of the money saved by the Department of Government Efficiency to Americans.
  
  CNBC - 1d

• What to know about Mitch McConnell's decision to retire

  Former Senate Majority leader Mitch McConnell will not seek reelection in 2026. CBS News congressional reporter Taurean Small reports.
  
  CBS News - 18h

More from MarketWatch

• FDA says Ozempic and Wegovy shortage is ending. That’s bad news for this wellness stock.

  “We will continue to offer access to personalized treatments as allowed by law to meet patient needs,” Hims & Hers CEO said.
  
  MarketWatch - 17m

• Can you trust Elon Musk and his ‘DOGE’ claims about government fraud?

  American people deserve answers about what these Washington outsiders-turned-insiders are up to
  
  MarketWatch - 23m

• Gold may soar past $3,000 — but at these prices you’re overpaying

  Why you can expect below-average returns from gold in coming years.
  
  MarketWatch - 32m

• Nvidia options traders are vastly overestimating how earnings will move the stock. Just look at these charts.

  Nvidia options aren’t a good trade, this expert says. Here’s what he likes.
  
  MarketWatch - 36m

• Warren Buffett’s 2025 letter to Berkshire shareholders is coming tomorrow. Watch this number.

  Even Buffett is struggling to outperform this bull market. Berkshire’s massive cash stake is key.
  
  MarketWatch - 41m

More in Business

• With tariffs ramping up, this investment option can provide protection against inflation

  The threat of tariffs on imports is causing some investors to consider increasing their exposure to TIPS to help buffer their portfolios against inflation.
  
  CNBC - 6m

• FDA says Ozempic and Wegovy shortage is ending. That’s bad news for this wellness stock.

  “We will continue to offer access to personalized treatments as allowed by law to meet patient needs,” Hims & Hers CEO said.
  
  MarketWatch - 17m

• Shares of Hims & Hers tumble 23% after FDA says semaglutide is no longer in shortage

  Shares of Hims & Hers tumble 23% after FDA says semaglutide is no longer in shortage
  
  CNBC - 23m
• 

  Is the Future of the Creator Economy Direct-to-Consumer?

  Confusion surrounding the TikTok ban last month has pushed creators to seek more stable ways to earn.
  
  Inc. - 23m

• Can you trust Elon Musk and his ‘DOGE’ claims about government fraud?

  American people deserve answers about what these Washington outsiders-turned-insiders are up to
  
  MarketWatch - 23m